HRP20180157T1 - Spojevi pirazolopirimidina kao jak-inhibitori i odgovarajući postupci - Google Patents
Spojevi pirazolopirimidina kao jak-inhibitori i odgovarajući postupci Download PDFInfo
- Publication number
- HRP20180157T1 HRP20180157T1 HRP20180157TT HRP20180157T HRP20180157T1 HR P20180157 T1 HRP20180157 T1 HR P20180157T1 HR P20180157T T HRP20180157T T HR P20180157TT HR P20180157 T HRP20180157 T HR P20180157T HR P20180157 T1 HRP20180157 T1 HR P20180157T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- colitis
- pyrazolo
- carboxamide
- methoxyphenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 7
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010056979 Colitis microscopic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010019842 Hepatomegaly Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000008609 collagenous colitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 208000027138 indeterminate colitis Diseases 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000004341 lymphocytic colitis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- HQPKFELLXBZWPT-UHFFFAOYSA-N n-[2-bromo-4-(5-chloro-2-methoxyphenyl)-1,3-thiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C1=C(NC(=O)C2=C3N=CC=CN3N=C2)SC(Br)=N1 HQPKFELLXBZWPT-UHFFFAOYSA-N 0.000 claims 1
- ROBUDMALQVGOOP-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)-1,3-thiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C1=C(NC(=O)C2=C3N=CC=CN3N=C2)SC=N1 ROBUDMALQVGOOP-UHFFFAOYSA-N 0.000 claims 1
- RZSYACKRHYHPKJ-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)-2-(2-hydroxy-2-methylpropyl)-1,3-thiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C1=C(NC(=O)C2=C3N=CC=CN3N=C2)SC(CC(C)(C)O)=N1 RZSYACKRHYHPKJ-UHFFFAOYSA-N 0.000 claims 1
- AVUQJQPWOCRGPQ-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)-2-(2-methylprop-1-enyl)-1,3-thiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C1=C(NC(=O)C2=C3N=CC=CN3N=C2)SC(C=C(C)C)=N1 AVUQJQPWOCRGPQ-UHFFFAOYSA-N 0.000 claims 1
- JWQCMPRXJOFEMC-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)-2-(oxan-4-yl)-1,3-thiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C1=C(NC(=O)C2=C3N=CC=CN3N=C2)SC(C2CCOCC2)=N1 JWQCMPRXJOFEMC-UHFFFAOYSA-N 0.000 claims 1
- XJIGRSGPENMQAL-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)-2-methyl-1,3-thiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C1=C(NC(=O)C2=C3N=CC=CN3N=C2)SC(C)=N1 XJIGRSGPENMQAL-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Claims (6)
1. Spoj, naznačen time, da je odabran od sljedećih:
N-(4-(5-kloro-2-metoksifenil)-2-(2-hidroksi-2-metilpropil)tiazol-5-il)pirazolo
[1,5-a]pirimidin-3-karboksamid;
N-(4-(5-kloro-2-metoksifenil)-2-(2-metilprop-1-enil)tiazol-5-il)pirazolo
[1,5-a]pirimidin-3-karboksamid;
N-(2-bromo-4-(5-kloro-2-metoksifenil)tiazol-5-il)pirazolo[1,5-a]pirimidin-3-karboksamid;
N-(4-(5-kloro-2-metoksifenil)tiazol-5-il)pirazolo[1,5-a]pirimidin-3-karboksamid;
N-(4-(5-kloro-2-metoksifenil)-2-metiltiazol-5-il)pirazolo[1,5-a]pirimidin-3-karboksamid;
N-(4-(5-kloro-2-metoksifenil)-2-(tetrahidro-2H-piran-4-il)tiazol-5-il)pirazolo
[1,5-a]pirimidin-3-karboksamid;
i njihove farmaceutski prihvatljive soli.
2. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 i farmaceutski prihvatljiv nosač, pomoćno sredstvo ili prijenosno sredstvo.
3. Spoj prema zahtjevu 1, naznačen time, da se upotrebljava u medicini.
4. Terapeutski učinkovita količina spoja prema zahtjevu 1, naznačena time, da se upotrebljava u prevenciji, liječenju ili smanjivanju težine bolesti ili stanja koja/koje je odabrana/odabrano od sljedećih: moždani udar, dijabetes, hepatomegalija, kardiovaskularna bolest, cistična fibroza, virusna bolest, autoimune bolesti, alergijski poremećaji, upala, neurološki poremećaji, bolest koja se odnosi na hormone, stanja povezana s transplantacijom organa, poremećaji imunodeficijencije, poremećaji destrukcije kostiju, proliferativni poremećaji, zarazne bolesti, stanja povezana sa smrću stanice, agregacija pločastih stanica inducirana trombinom, bolesti jetre, patološka imuna stanja koja uključuju aktiviranje T-stanice, CNS poremećaji, ili mijeloproliferativni poremećaj.
5. Spoj za uporabu prema zahtjevu 4, naznačen time, da je bolest ili stanje odabrana/odabrano od sljedećih:
rak;
kardiovaskularna bolest odabrana od restenoze, kardiomegalije, ateroskleroze, infarkta miokarda ili kongestivnog srčanog zastoja;
neurološki poremećaj koji je neurodegenerativna bolest odabrana od Alzheimerove bolesti, Parkinsonove bolesti, amiotrofne lateralne skleroze, Huntingtonove bolesti i cerebralne ishemije;
upala koja je upalna bolest odabrana od upalne bolesti crijeva, reumatoidnog artritisa, psorijaze, kontaktnog dermatitisa, ili odgođenih hipersenzitivnih reakcija;
autoimuna bolest odabrana od lupusa ili multiple skleroze, Crohnove bolesti, ulcerativnog kolitisa, kolagenoznog kolitisa, limfocitnog kolitisa, ishemijskog kolitisa, diverzijskog kolitisa, Behçetovog sindroma, infektivnog kolitisa i neodređenog kolitisa; i
psorijaza.
6. Spoj za uporabu prema zahtjevu 3, naznačen time, da se upotrebljava u prevenciji, liječenju ili smanjivanju težine bolesti ili stanja koja/koje je odabrana/odabrano od sljedećih: rak, policitemija vera, esencijalna trombocitoza, mijelofibroza, kronična mijelogena leukemija (CML), reumatoidni artritis, kronična upalna crijevna bolest, Crohnova bolest, psorijaza, kontaktni dermatitis ili odgođene hipersenzitivne reakcije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22291809P | 2009-07-02 | 2009-07-02 | |
| PCT/US2010/040906 WO2011003065A2 (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
| EP10794815.0A EP2448941B1 (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180157T1 true HRP20180157T1 (hr) | 2018-03-09 |
Family
ID=43411778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180157TT HRP20180157T1 (hr) | 2009-07-02 | 2018-01-26 | Spojevi pirazolopirimidina kao jak-inhibitori i odgovarajući postupci |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US8999998B2 (hr) |
| EP (3) | EP2448941B1 (hr) |
| JP (4) | JP5769261B2 (hr) |
| KR (3) | KR101903305B1 (hr) |
| CN (2) | CN102482284B (hr) |
| AU (1) | AU2010266188B2 (hr) |
| BR (1) | BRPI1010197A2 (hr) |
| CA (1) | CA2767097A1 (hr) |
| CL (1) | CL2012000001A1 (hr) |
| CO (1) | CO6491081A2 (hr) |
| CR (2) | CR20170115A (hr) |
| DK (1) | DK2448941T3 (hr) |
| EC (1) | ECSP12011645A (hr) |
| ES (1) | ES2657839T3 (hr) |
| HR (1) | HRP20180157T1 (hr) |
| HU (1) | HUE035537T2 (hr) |
| IL (3) | IL217224B (hr) |
| IN (1) | IN2012DN00755A (hr) |
| LT (1) | LT2448941T (hr) |
| MA (1) | MA33502B1 (hr) |
| MX (1) | MX2012000169A (hr) |
| MY (1) | MY160156A (hr) |
| NO (1) | NO2448941T3 (hr) |
| NZ (4) | NZ738778A (hr) |
| PE (2) | PE20120575A1 (hr) |
| PH (1) | PH12015500666A1 (hr) |
| PL (1) | PL2448941T3 (hr) |
| PT (1) | PT2448941T (hr) |
| RS (1) | RS56671B1 (hr) |
| RU (2) | RU2675857C2 (hr) |
| SG (2) | SG177454A1 (hr) |
| SI (1) | SI2448941T1 (hr) |
| UA (1) | UA110324C2 (hr) |
| WO (1) | WO2011003065A2 (hr) |
| ZA (2) | ZA201200490B (hr) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| WO2008157208A2 (en) | 2007-06-13 | 2008-12-24 | Incyte Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| JP5769199B2 (ja) | 2008-10-31 | 2015-08-26 | ジェネンテック， インコーポレイテッド | ピラゾロピリミジンｊａｋ阻害剤化合物と方法 |
| PE20120371A1 (es) | 2009-05-22 | 2012-05-17 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| MX364636B (es) | 2010-03-10 | 2019-05-03 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| ES2601004T3 (es) | 2010-04-07 | 2017-02-13 | F. Hoffmann-La Roche Ag | Compuestos pirazol-4-il-heterociclil-carboxamida y métodos de uso |
| KR102040479B1 (ko) | 2010-05-21 | 2019-11-06 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 저해제에 대한 국소 제형 |
| KR101995013B1 (ko) * | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| CN103619171B (zh) | 2010-11-03 | 2015-11-25 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| WO2012067822A1 (en) * | 2010-11-16 | 2012-05-24 | Abbott Laboratories | Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2688872A4 (en) * | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
| US8859549B2 (en) | 2011-05-13 | 2014-10-14 | Abbvie, Inc. | Potassium channel modulators |
| BR112013032720A2 (pt) | 2011-06-20 | 2016-09-13 | Incyte Corp | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TWI570117B (zh) | 2011-09-27 | 2017-02-11 | 赫孚孟拉羅股份公司 | 吡唑－４－基－雜環甲醯胺化合物及使用方法 |
| DK2760867T3 (en) | 2011-09-30 | 2016-04-11 | Oncodesign Sa | Macrocyclic FLT3 kinase inhibitors |
| JP6027128B2 (ja) | 2011-10-26 | 2016-11-16 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除組成物およびそれに関連した方法 |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| JP6463670B2 (ja) | 2012-04-27 | 2019-02-06 | ダウ アグロサイエンシィズ エルエルシー | 農薬組成物およびそれらに関する方法 |
| US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| KR20150041651A (ko) * | 2012-08-10 | 2015-04-16 | 에프. 호프만-라 로슈 아게 | 피라졸 카복스아미드 화합물, 조성물 및 사용 방법 |
| CN103073549A (zh) * | 2012-09-07 | 2013-05-01 | 苏州康润医药有限公司 | 3-溴吡唑啉[1,5-α]吡嘧啶-2-甲酸的合成工艺 |
| CA2880326A1 (en) | 2012-10-26 | 2014-05-01 | F. Hoffmann-La Roche Ag | 3,4-disubstituted 1 h-pyrazole and 4,5-disubstituted thiazole inhibitors of syk cap |
| AU2013344780B2 (en) | 2012-11-15 | 2018-03-01 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
| PL2941432T3 (pl) * | 2012-12-07 | 2018-09-28 | Vertex Pharmaceuticals Incorporated | 2-Amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oksetan-3-ylo)piperazyno-1-karbonylo)piperydyn-1-ylo)pirydyn-3-ylo)pirazoto[1,5alfa]pirymidino-3-karboksyamid jako inhibitor kinazy ATR |
| WO2014118388A1 (en) | 2013-02-04 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| RS58547B1 (sr) | 2013-03-06 | 2019-05-31 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| EP2970286A1 (en) * | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| WO2014143241A1 (en) * | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2014143242A1 (en) * | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| PT3030227T (pt) | 2013-08-07 | 2020-06-25 | Incyte Corp | Formas de dosagem de libertação prolongada para um inibidor de jak1 |
| WO2015058023A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| WO2015058026A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| WO2015058024A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| WO2015058022A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| JP2016539092A (ja) | 2013-10-17 | 2016-12-15 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
| MX2016004948A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de un compuesto pesticida. |
| EP3057429A4 (en) | 2013-10-17 | 2017-08-09 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
| JP2016539930A (ja) | 2013-10-22 | 2016-12-22 | ダウ アグロサイエンシィズ エルエルシー | 農薬組成物および関連する方法 |
| CA2927195A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| WO2015061155A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| WO2015061151A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| NZ719968A (en) | 2013-10-22 | 2017-05-26 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| WO2015061140A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| MX2016005317A (es) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Composiciones pesticidas y metodos relacionados. |
| AU2014340443B2 (en) | 2013-10-22 | 2017-06-08 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| AU2014340437B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| WO2015061147A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| AU2014340428B2 (en) | 2013-10-22 | 2017-06-29 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| AU2014340442A1 (en) | 2013-10-22 | 2016-06-02 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| TW201519779A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 協同性殺蟲組成物及相關方法（十二） |
| AR098095A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas y los métodos relacionados |
| NZ720023A (en) | 2013-10-22 | 2017-09-29 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| MX2016005325A (es) | 2013-10-22 | 2016-08-08 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
| AU2014340409B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| ES2777123T3 (es) * | 2013-11-08 | 2020-08-03 | Takeda Pharmaceuticals Co | Pirazol para el tratamiento de trastornos autoinmunes |
| CN104650092B (zh) * | 2013-11-16 | 2017-11-10 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| EP3077393A1 (en) * | 2013-12-06 | 2016-10-12 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2015085132A1 (en) * | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| MX2016012021A (es) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| US9493439B1 (en) | 2014-04-07 | 2016-11-15 | University Of Kentucky Research Foundation | Proteasome inhibitors |
| DK3129021T3 (da) * | 2014-04-08 | 2020-11-09 | Incyte Corp | Behandling af b-celle-maligniteter ved en kombination af jak- og pi3k-inhibitorer |
| EA032488B1 (ru) * | 2014-05-23 | 2019-06-28 | Ф. Хоффманн-Ля Рош Аг | Соединения 5-хлор-дифторметоксифенилпиразолопиримидина, представляющие собой ингибиторы янус-киназы |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US9670215B2 (en) * | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2015195740A1 (en) | 2014-06-17 | 2015-12-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
| BR112017000418A2 (pt) | 2014-07-31 | 2017-11-07 | Dow Agrosciences Llc | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina |
| KR20170039121A (ko) | 2014-07-31 | 2017-04-10 | 다우 아그로사이언시즈 엘엘씨 | 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법 |
| CA2954345A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| AR098112A1 (es) | 2014-08-19 | 2016-05-04 | Dow Agrosciences Llc | Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina |
| CA2960985A1 (en) | 2014-09-12 | 2016-03-17 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| WO2016202898A1 (en) * | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| AU2016322552B2 (en) | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| US10544139B2 (en) | 2015-11-06 | 2020-01-28 | Samumed, Llc | Treatment of osteoarthritis |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| EP3416967B1 (en) | 2016-02-18 | 2022-02-09 | F. Hoffmann-La Roche AG | Therapeutic compounds, compositions and methods of use thereof |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106008525B (zh) * | 2016-06-16 | 2018-08-07 | 南京工业大学 | 一种小分子有机纳米肿瘤光热治疗试剂及其制备方法 |
| US10233155B2 (en) | 2016-12-29 | 2019-03-19 | Dow Agrosciences Llc | Processes for the preparation of pesticide compounds |
| MA47167A (fr) | 2016-12-29 | 2019-11-06 | Hoffmann La Roche | Composés pyrazolopyrimidine et leurs procédés d'utilisation |
| US10100033B2 (en) | 2016-12-29 | 2018-10-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| LT3571192T (lt) * | 2017-01-17 | 2023-02-27 | Astrazeneca Ab | Jak1 atžvilgiu selektyvūs inhibitoriai |
| EP3596072B1 (en) * | 2017-03-14 | 2022-06-22 | F. Hoffmann-La Roche AG | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| PL233595B1 (pl) * | 2017-05-12 | 2019-11-29 | Celon Pharma Spolka Akcyjna | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK |
| CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| SG11201909735YA (en) * | 2017-05-22 | 2019-11-28 | Hoffmann La Roche | Therapeutic compounds and compositions, and methods of use thereof |
| EP3655402A1 (de) | 2017-07-18 | 2020-05-27 | Bayer CropScience Aktiengesellschaft | Substituierte 3-heteroaryloxy-1h-pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| CN107686456B (zh) * | 2017-07-25 | 2018-10-23 | 杭州师范大学 | 一种喹喏酮关键中间体乙酯胺化物及其制备方法和应用 |
| CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| WO2019139714A1 (en) | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Pyrazolopyrimidine compounds as jak inhibitors |
| MX2020007521A (es) * | 2018-01-17 | 2022-12-05 | Glaxosmithkline Ip Dev Ltd | Inhibidores de pi4kiii. |
| CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
| CN110476009A (zh) | 2018-03-07 | 2019-11-19 | 三菱化学株式会社 | 透明树脂组合物、树脂成型体、灯罩、车辆用灯罩、组合灯罩和车辆 |
| MX2022012285A (es) | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
| EP3775923A1 (en) * | 2018-04-13 | 2021-02-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| EP3911317A2 (en) * | 2019-01-17 | 2021-11-24 | BioSplice Therapeutics, Inc. | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| PE20220577A1 (es) * | 2019-06-18 | 2022-04-20 | Hoffmann La Roche | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos |
| EP3986900A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof |
| EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2022256358A1 (en) | 2021-06-03 | 2022-12-08 | Genentech, Inc. | Process for preparing medicaments |
| CN115466227A (zh) * | 2022-06-30 | 2022-12-13 | 杭州国瑞生物科技有限公司 | 一种3-(氯甲基)-1-甲基-1h-1,2,4-三唑盐酸盐的制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8401486A1 (es) | 1981-11-10 | 1983-12-01 | Wellcome Found | Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina. |
| US4602035A (en) | 1983-12-07 | 1986-07-22 | Hoechst-Roussel Pharmaceuticals Inc. | Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines |
| US4847256A (en) | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
| US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5705625A (en) | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
| US7070972B1 (en) | 1995-01-13 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Janus family kinases and identification of immune modulators |
| US7091020B1 (en) | 1995-12-05 | 2006-08-15 | Incyte Corporation | Human Jak2 kinase |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| FR2791562B1 (fr) | 1999-03-29 | 2004-03-05 | Oreal | Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture |
| US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| MXPA02005675A (es) * | 1999-12-10 | 2002-09-02 | Pfizer Prod Inc | Compuestos de pirrolo(2,3-d)pirimidina. |
| CN100343255C (zh) | 2002-04-23 | 2007-10-17 | 盐野义制药株式会社 | 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂 |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| CA2502429A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| US20070270408A1 (en) | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| WO2005004810A2 (en) | 2003-07-02 | 2005-01-20 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| RS51830B (en) * | 2004-03-30 | 2012-02-29 | Vertex Pharmaceuticals Incorporated | AZAINDOLES USEFUL AS INHIBITORS OF STRENGTH AND OTHER PROTEIN KINASES |
| US20060030536A1 (en) | 2004-04-09 | 2006-02-09 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
| EP1751159A2 (en) | 2004-04-28 | 2007-02-14 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
| JP2008504294A (ja) | 2004-06-25 | 2008-02-14 | アムジエン・インコーポレーテツド | サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール |
| DE602005023763D1 (de) | 2004-11-04 | 2010-11-04 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine |
| EP1910369A1 (en) | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| WO2007039797A1 (en) | 2005-10-03 | 2007-04-12 | Pfizer Products Inc. | Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis |
| US7645762B2 (en) | 2005-10-06 | 2010-01-12 | Schering Corporation | Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors |
| AU2006299338A1 (en) * | 2005-10-06 | 2007-04-12 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidines as protein kinase inhibitors |
| WO2007048064A2 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Amino-pyrimidines as casein kinase ii (ck2) modulators |
| EP1963316A2 (en) | 2005-12-08 | 2008-09-03 | Novartis AG | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
| US8541406B2 (en) * | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| MX2008012860A (es) * | 2006-04-05 | 2009-01-07 | Vertex Pharma | Desazapurinas de utilidad como inhibidores de janus cinasas. |
| KR20150140872A (ko) | 2006-06-02 | 2015-12-16 | 니뽄 신야쿠 가부시키가이샤 | 9,10-세코프레그난 유도체 및 의약 |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| JP2010508315A (ja) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
| WO2008063671A2 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CA2702008A1 (en) * | 2007-10-12 | 2009-04-16 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| CN104327084B (zh) | 2007-11-28 | 2017-06-06 | 达那-法伯癌症研究所 | Bcr‑abl的小分子豆蔻酸酯抑制剂及其使用方法 |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| US8252791B2 (en) | 2008-08-13 | 2012-08-28 | Jenrin Discovery, Inc. | Purine compounds as cannabinoid receptor blockers |
| JP5769199B2 (ja) * | 2008-10-31 | 2015-08-26 | ジェネンテック， インコーポレイテッド | ピラゾロピリミジンｊａｋ阻害剤化合物と方法 |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| CA2748862A1 (en) | 2009-02-06 | 2010-08-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011048082A1 (en) | 2009-10-20 | 2011-04-28 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| MX2012010265A (es) | 2010-03-17 | 2012-10-01 | Hoffmann La Roche | Compuestos de imidazopiridina, composiciones y metodos de uso. |
| EA201291038A1 (ru) | 2010-04-30 | 2013-05-30 | Целльзом Лимитид | Соединения пиразола в качестве ингибиторов jak |
-
2010
- 2010-02-07 UA UAA201201035A patent/UA110324C2/uk unknown
- 2010-07-02 PL PL10794815T patent/PL2448941T3/pl unknown
- 2010-07-02 EP EP10794815.0A patent/EP2448941B1/en active Active
- 2010-07-02 NZ NZ738778A patent/NZ738778A/en not_active IP Right Cessation
- 2010-07-02 NZ NZ706218A patent/NZ706218A/en not_active IP Right Cessation
- 2010-07-02 CA CA2767097A patent/CA2767097A1/en not_active Abandoned
- 2010-07-02 IN IN755DEN2012 patent/IN2012DN00755A/en unknown
- 2010-07-02 RU RU2015133989A patent/RU2675857C2/ru not_active IP Right Cessation
- 2010-07-02 LT LTEP10794815.0T patent/LT2448941T/lt unknown
- 2010-07-02 KR KR1020177012984A patent/KR101903305B1/ko active IP Right Grant
- 2010-07-02 EP EP17192475.6A patent/EP3333169B1/en active Active
- 2010-07-02 RS RS20171278A patent/RS56671B1/sr unknown
- 2010-07-02 NO NO10794815A patent/NO2448941T3/no unknown
- 2010-07-02 KR KR1020187027109A patent/KR20180108858A/ko not_active Application Discontinuation
- 2010-07-02 PT PT107948150T patent/PT2448941T/pt unknown
- 2010-07-02 SG SG2011097623A patent/SG177454A1/en unknown
- 2010-07-02 SI SI201031625T patent/SI2448941T1/en unknown
- 2010-07-02 MY MYPI2011006384A patent/MY160156A/en unknown
- 2010-07-02 NZ NZ719972A patent/NZ719972A/en not_active IP Right Cessation
- 2010-07-02 JP JP2012517917A patent/JP5769261B2/ja active Active
- 2010-07-02 ES ES10794815.0T patent/ES2657839T3/es active Active
- 2010-07-02 NZ NZ622283A patent/NZ622283A/en not_active IP Right Cessation
- 2010-07-02 BR BRPI1010197A patent/BRPI1010197A2/pt not_active Application Discontinuation
- 2010-07-02 HU HUE10794815A patent/HUE035537T2/en unknown
- 2010-07-02 CN CN201080039041.1A patent/CN102482284B/zh active Active
- 2010-07-02 CN CN201510276276.7A patent/CN104910161B/zh active Active
- 2010-07-02 KR KR1020127002790A patent/KR101825754B1/ko active IP Right Grant
- 2010-07-02 AU AU2010266188A patent/AU2010266188B2/en not_active Ceased
- 2010-07-02 WO PCT/US2010/040906 patent/WO2011003065A2/en active Application Filing
- 2010-07-02 DK DK10794815.0T patent/DK2448941T3/en active
- 2010-07-02 PE PE2012000003A patent/PE20120575A1/es active IP Right Grant
- 2010-07-02 PE PE2015000692A patent/PE20151249A1/es not_active Application Discontinuation
- 2010-07-02 MX MX2012000169A patent/MX2012000169A/es active IP Right Grant
- 2010-07-02 EP EP19211640.8A patent/EP3670514A1/en not_active Withdrawn
- 2010-07-02 MA MA34594A patent/MA33502B1/fr unknown
- 2010-07-02 US US13/382,145 patent/US8999998B2/en active Active
- 2010-07-02 RU RU2012103487/04A patent/RU2567238C2/ru not_active IP Right Cessation
- 2010-07-02 SG SG10201509607XA patent/SG10201509607XA/en unknown
- 2010-07-02 CR CR20170115A patent/CR20170115A/es unknown
-
2011
- 2011-12-27 IL IL217224A patent/IL217224B/en not_active IP Right Cessation
-
2012
- 2012-01-02 CL CL2012000001A patent/CL2012000001A1/es unknown
- 2012-01-20 ZA ZA2012/00490A patent/ZA201200490B/en unknown
- 2012-01-25 CO CO12011326A patent/CO6491081A2/es active IP Right Grant
- 2012-01-30 CR CR20120053A patent/CR20120053A/es unknown
- 2012-02-02 EC ECSP12011645 patent/ECSP12011645A/es unknown
-
2013
- 2013-10-02 ZA ZA2013/07356A patent/ZA201307356B/en unknown
-
2015
- 2015-02-06 US US14/615,873 patent/US20150152117A1/en not_active Abandoned
- 2015-03-25 PH PH12015500666A patent/PH12015500666A1/en unknown
- 2015-06-17 JP JP2015122441A patent/JP6312634B2/ja active Active
- 2015-12-09 IL IL242999A patent/IL242999B/en not_active IP Right Cessation
-
2017
- 2017-06-20 US US15/627,847 patent/US20170283424A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000305A patent/JP2018083828A/ja not_active Withdrawn
- 2018-01-15 IL IL256921A patent/IL256921A/en unknown
- 2018-01-26 HR HRP20180157TT patent/HRP20180157T1/hr unknown
-
2019
- 2019-06-07 JP JP2019106948A patent/JP2019194199A/ja active Pending
- 2019-09-05 US US16/561,432 patent/US20200002345A1/en not_active Abandoned
-
2022
- 2022-01-14 US US17/648,045 patent/US20220389020A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180157T1 (hr) | Spojevi pirazolopirimidina kao jak-inhibitori i odgovarajući postupci | |
| HRP20161291T1 (hr) | Soli fenotiazin-diamina i njihova uporaba | |
| HRP20160185T1 (hr) | Spojevi iminotiadiazin dioksida kao inhibitori bace, smjese i njihova uporaba | |
| JP2010509230A5 (hr) | ||
| HRP20170359T1 (hr) | Kamsilatna sol (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njezini kristalni oblici za liječenje [beta]-povezanih patologija kao što je npr. alzheimerova bolest | |
| JP2012532112A5 (hr) | ||
| JP2015500223A5 (hr) | ||
| PH12014501178A1 (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12017501911A1 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| AR080792A1 (es) | Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias. | |
| WO2014040010A3 (en) | Cleaning compositions comprising structured particles | |
| MX2009009793A (es) | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. | |
| AR093340A1 (es) | Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por cftr, granulo, comprimido, proceso continuo para la preparacion de un comprimido | |
| JP2013116921A5 (hr) | ||
| CN101845176B (zh) | 汽车用防撞击材料 | |
| JP2013533314A5 (hr) | ||
| JP2011509303A5 (hr) | ||
| JP2015520221A5 (hr) | ||
| HRP20161730T1 (hr) | Postupak proizvodnje čvrstih oralnih doznih oblika solifenacina i njegovih farmaceutski prikladnih soli | |
| JP2009511591A5 (hr) | ||
| FI3487505T3 (fi) | Diaminofenotiatsiinien antaminen ja annostus | |
| JP2009519988A5 (hr) | ||
| JP2008526953A5 (hr) | ||
| JP2015526455A5 (hr) | ||
| JP2016507526A5 (hr) |